Symbols / TIVC Stock $1.40 Tivic Health Systems Inc
TIVC (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteValion Bio, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Ratings
- Tivic rebrands as Valion Bio, centering Entolimod and CDMO unit - Stock Titan hu, 23 Apr 2026 07
- Tivic Health Systems (TIVC) Stock Surges Over 24% After Hours: Here's What Is Happening - Benzinga Fri, 24 Apr 2026 07
- Tivic Health Systems Stock (TIVC) Opinions on Emerging Growth Conference Presentation - Quiver Quantitative hu, 02 Apr 2026 07
- $TIVC stock is up 15% today. Here's what we see in our data. - Quiver Quantitative Fri, 24 Apr 2026 07
- Valion Bio (VBIO) widens Q1 2026 loss as it builds TLR5 and CDMO platform - Stock Titan hu, 14 May 2026 20
- Tivic Health Rebrands as Valion Bio, Sharpening Biopharma Focus - TipRanks hu, 23 Apr 2026 07
- Valion Bio (VBIO) grants 45,000 stock options to general counsel - Stock Titan Mon, 04 May 2026 07
- Biotech leader behind 17 drug launches now steering Tivic’s biopharma pivot - Stock Titan Wed, 04 Mar 2026 08
- Insider Purchase: Director at $TIVC Buys 10,000 Shares - Quiver Quantitative Mon, 20 Apr 2026 07
- 3i group (TIVC) files amendment showing 9.99% holding and convertible exposure - Stock Titan Fri, 08 May 2026 07
- Valion Bio (VBIO) General Counsel Melinda Lackey becomes reporting insider with Form 3 - Stock Titan Mon, 04 May 2026 07
- Tivic pitches a faster radiation treatment concept to U.S. War Tech Watch - Stock Titan Wed, 15 Apr 2026 07
- Tivic drops its sinus device to focus on radiation and cancer treatments - Stock Titan ue, 24 Mar 2026 07
- Valion Bio (Nasdaq: VBIO) hires Melinda Lackey as General Counsel - Stock Titan Mon, 04 May 2026 07
- Tivic to detail in-house Entolimod manufacturing, new revenue streams - Stock Titan ue, 20 Jan 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
-100.00%
|
1.18
-36.09%
|
1.84
|
| Operating Revenue |
|
0.00
|
0.00
-100.00%
|
1.18
-36.09%
|
1.84
|
| Cost Of Revenue |
|
—
|
0.78
-12.49%
|
0.89
-42.31%
|
1.54
|
| Reconciled Cost Of Revenue |
|
—
|
0.78
-12.49%
|
0.89
-42.31%
|
1.54
|
| Gross Profit |
|
—
|
0.00
-99.30%
|
0.29
-4.01%
|
0.30
|
| Operating Expense |
|
7.90
+76.45%
|
4.48
-47.54%
|
8.53
-17.94%
|
10.40
|
| Research And Development |
|
3.13
+138.46%
|
1.31
-20.66%
|
1.66
-4.34%
|
1.73
|
| Selling General And Administration |
|
4.77
+50.71%
|
3.16
-54.01%
|
6.88
-20.65%
|
8.67
|
| Selling And Marketing Expense |
|
—
|
1.19
-44.14%
|
2.12
-23.89%
|
2.79
|
| General And Administrative Expense |
|
4.77
+50.71%
|
3.16
-33.44%
|
4.75
-19.11%
|
5.88
|
| Other Gand A |
|
4.77
+50.71%
|
3.16
-33.44%
|
4.75
-19.11%
|
5.88
|
| Total Expenses |
|
7.90
+76.45%
|
4.48
-52.49%
|
9.42
-21.08%
|
11.94
|
| Operating Income |
|
-7.90
-76.45%
|
-4.48
+45.71%
|
-8.24
+18.35%
|
-10.10
|
| Total Operating Income As Reported |
|
-7.90
-76.45%
|
-4.48
+45.71%
|
-8.24
+18.35%
|
-10.10
|
| EBITDA |
|
-7.84
-90.43%
|
-4.12
+48.93%
|
-8.06
+18.75%
|
-9.92
|
| Normalized EBITDA |
|
-7.87
-91.11%
|
-4.12
+48.93%
|
-8.06
+18.75%
|
-9.92
|
| Reconciled Depreciation |
|
0.01
-98.58%
|
0.35
+93.41%
|
0.18
+4.60%
|
0.17
|
| EBIT |
|
-7.85
-75.55%
|
-4.47
+45.79%
|
-8.24
+18.35%
|
-10.10
|
| Total Unusual Items |
|
0.03
|
—
|
—
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
0.03
|
—
|
—
|
0.00
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-8.88
-56.99%
|
-5.66
+31.40%
|
-8.24
+18.34%
|
-10.10
|
| Pretax Income |
|
-7.99
-78.81%
|
-4.47
+45.78%
|
-8.24
+18.34%
|
-10.10
|
| Net Non Operating Interest Income Expense |
|
-0.12
-2150.00%
|
0.01
+500.00%
|
0.00
-50.00%
|
0.00
|
| Interest Expense Non Operating |
|
0.15
|
0.00
|
—
|
—
|
| Net Interest Income |
|
-0.12
-2150.00%
|
0.01
+500.00%
|
0.00
-50.00%
|
0.00
|
| Interest Expense |
|
0.15
|
0.00
|
—
|
—
|
| Interest Income Non Operating |
|
0.02
+283.33%
|
0.01
+500.00%
|
0.00
-50.00%
|
0.00
|
| Interest Income |
|
0.02
+283.33%
|
0.01
+500.00%
|
0.00
-50.00%
|
0.00
|
| Other Income Expense |
|
0.03
|
—
|
—
|
—
|
| Other Non Operating Income Expenses |
|
—
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
0.03
|
—
|
—
|
—
|
| Tax Provision |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-8.88
-56.99%
|
-5.66
+31.40%
|
-8.24
+18.34%
|
-10.10
|
| Net Income From Continuing Operation Net Minority Interest |
|
-7.99
-78.81%
|
-4.47
+45.78%
|
-8.24
+18.34%
|
-10.10
|
| Net Income From Continuing And Discontinued Operation |
|
-8.88
-56.99%
|
-5.66
+31.40%
|
-8.24
+18.34%
|
-10.10
|
| Net Income Continuous Operations |
|
-7.99
-78.81%
|
-4.47
+45.78%
|
-8.24
+18.34%
|
-10.10
|
| Net Income Discontinuous Operations |
|
-0.89
+25.32%
|
-1.19
|
—
|
—
|
| Normalized Income |
|
-8.02
-79.44%
|
-4.47
+45.78%
|
-8.24
+18.34%
|
-10.10
|
| Net Income Common Stockholders |
|
-8.88
-56.99%
|
-5.66
+31.40%
|
-8.24
+18.34%
|
-10.10
|
| Diluted EPS |
|
—
|
-19.68
+88.87%
|
-176.80
+90.00%
|
-1,768.00
|
| Basic EPS |
|
—
|
-19.68
+88.87%
|
-176.80
+90.00%
|
-1,768.00
|
| Basic Average Shares |
|
—
|
0.29
+516.01%
|
0.05
+720.00%
|
0.01
|
| Diluted Average Shares |
|
—
|
0.29
+516.01%
|
0.05
+720.00%
|
0.01
|
| Diluted NI Availto Com Stockholders |
|
-8.88
-56.99%
|
-5.66
+31.40%
|
-8.24
+18.34%
|
-10.10
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
-0.00
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
5.16
|
| Current Assets |
|
4.65
|
| Cash Cash Equivalents And Short Term Investments |
|
3.40
|
| Cash And Cash Equivalents |
|
3.40
|
| Receivables |
|
0.17
|
| Accounts Receivable |
|
0.17
|
| Gross Accounts Receivable |
|
—
|
| Allowance For Doubtful Accounts Receivable |
|
—
|
| Inventory |
|
0.76
|
| Raw Materials |
|
0.75
|
| Work In Process |
|
0.00
|
| Finished Goods |
|
0.04
|
| Prepaid Assets |
|
—
|
| Current Deferred Assets |
|
0.00
|
| Assets Held For Sale Current |
|
—
|
| Other Current Assets |
|
0.33
|
| Total Non Current Assets |
|
0.51
|
| Net PPE |
|
0.47
|
| Gross PPE |
|
0.51
|
| Accumulated Depreciation |
|
-0.04
|
| Properties |
|
0.00
|
| Buildings And Improvements |
|
0.35
|
| Machinery Furniture Equipment |
|
0.01
|
| Other Properties |
|
0.15
|
| Goodwill And Other Intangible Assets |
|
—
|
| Other Intangible Assets |
|
—
|
| Non Current Deferred Assets |
|
0.00
|
| Other Non Current Assets |
|
0.03
|
| Total Liabilities Net Minority Interest |
|
1.58
|
| Current Liabilities |
|
1.40
|
| Payables And Accrued Expenses |
|
1.21
|
| Payables |
|
0.87
|
| Accounts Payable |
|
0.71
|
| Current Accrued Expenses |
|
0.34
|
| Total Tax Payable |
|
0.16
|
| Current Debt And Capital Lease Obligation |
|
0.19
|
| Current Capital Lease Obligation |
|
0.19
|
| Other Current Liabilities |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.18
|
| Liabilities Heldfor Sale Non Current |
|
—
|
| Long Term Debt And Capital Lease Obligation |
|
0.18
|
| Long Term Debt |
|
—
|
| Long Term Capital Lease Obligation |
|
0.18
|
| Other Non Current Liabilities |
|
—
|
| Preferred Securities Outside Stock Equity |
|
—
|
| Stockholders Equity |
|
3.58
|
| Common Stock Equity |
|
3.58
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
0.09
|
| Ordinary Shares Number |
|
0.09
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
41.47
|
| Retained Earnings |
|
-37.89
|
| Total Equity Gross Minority Interest |
|
3.58
|
| Total Capitalization |
|
3.58
|
| Working Capital |
|
3.25
|
| Invested Capital |
|
3.58
|
| Total Debt |
|
0.37
|
| Capital Lease Obligations |
|
0.37
|
| Net Tangible Assets |
|
3.58
|
| Tangible Book Value |
|
3.58
|
| Derivative Product Liabilities |
|
—
|
| Inventories Adjustments Allowances |
|
-0.03
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-7.00
-22.25%
|
-5.72
+32.73%
|
-8.51
+4.57%
|
-8.92
|
| Cash Flow From Continuing Operating Activities |
|
-6.62
-30.24%
|
-5.08
+40.29%
|
-8.51
+4.57%
|
-8.92
|
| Cash From Discontinued Operating Activities |
|
-0.38
+40.90%
|
-0.64
|
—
|
—
|
| Net Income From Continuing Operations |
|
-7.99
-78.81%
|
-4.47
+45.78%
|
-8.24
+18.34%
|
-10.10
|
| Depreciation Amortization Depletion |
|
0.01
-98.58%
|
0.35
+93.41%
|
0.18
+4.60%
|
0.17
|
| Depreciation |
|
0.01
-98.58%
|
0.35
+93.41%
|
0.18
+4.60%
|
0.17
|
| Depreciation And Amortization |
|
0.01
-98.58%
|
0.35
+93.41%
|
0.18
+4.60%
|
0.17
|
| Other Non Cash Items |
|
0.24
|
—
|
—
|
—
|
| Stock Based Compensation |
|
0.56
+146.29%
|
0.23
-15.50%
|
0.27
-31.91%
|
0.40
|
| Provisionand Write Offof Assets |
|
—
|
0.35
+1006.25%
|
0.03
|
0.00
|
| Asset Impairment Charge |
|
0.14
|
0.00
|
—
|
—
|
| Operating Gains Losses |
|
-0.03
|
—
|
—
|
—
|
| Gain Loss On Investment Securities |
|
-0.03
|
—
|
—
|
—
|
| Change In Working Capital |
|
0.45
+137.89%
|
-1.19
-58.64%
|
-0.75
-224.30%
|
0.60
|
| Change In Receivables |
|
—
|
0.10
+256.72%
|
-0.07
-6800.00%
|
0.00
|
| Changes In Account Receivables |
|
—
|
0.10
+256.72%
|
-0.07
-6800.00%
|
0.00
|
| Change In Inventory |
|
—
|
0.08
+10.67%
|
0.07
+117.28%
|
-0.43
|
| Change In Prepaid Assets |
|
0.08
+0.00%
|
0.08
+184.78%
|
-0.09
-116.49%
|
0.56
|
| Change In Payables And Accrued Expense |
|
0.37
+139.96%
|
-0.94
-84.62%
|
-0.51
-178.85%
|
0.64
|
| Change In Accrued Expense |
|
0.23
+167.53%
|
-0.35
-437.86%
|
0.10
-5.50%
|
0.11
|
| Change In Payable |
|
0.14
+123.64%
|
-0.59
+3.61%
|
-0.61
-214.23%
|
0.53
|
| Change In Account Payable |
|
0.14
+123.64%
|
-0.59
+3.61%
|
-0.61
-214.23%
|
0.53
|
| Change In Other Current Assets |
|
0.00
-100.00%
|
0.03
|
0.00
-100.00%
|
0.01
|
| Change In Other Current Liabilities |
|
0.00
+100.00%
|
-0.37
-129.19%
|
-0.16
+9.55%
|
-0.18
|
| Investing Cash Flow |
|
-0.70
|
0.00
+100.00%
|
-0.12
-972.73%
|
-0.01
|
| Cash Flow From Continuing Investing Activities |
|
-0.70
|
0.00
+100.00%
|
-0.12
-972.73%
|
-0.01
|
| Net PPE Purchase And Sale |
|
-0.04
|
0.00
+100.00%
|
-0.12
-972.73%
|
-0.01
|
| Purchase Of PPE |
|
-0.04
|
0.00
+100.00%
|
-0.12
-972.73%
|
-0.01
|
| Capital Expenditure |
|
-0.58
|
—
|
-0.12
-972.73%
|
-0.01
|
| Net Investment Purchase And Sale |
|
-0.12
|
0.00
|
—
|
—
|
| Purchase Of Investment |
|
-0.12
|
0.00
|
—
|
—
|
| Net Intangibles Purchase And Sale |
|
-0.54
|
0.00
|
—
|
—
|
| Purchase Of Intangibles |
|
-0.54
|
0.00
|
—
|
—
|
| Financing Cash Flow |
|
18.35
+323.52%
|
4.33
-49.08%
|
8.51
+1711.17%
|
-0.53
|
| Cash Flow From Continuing Financing Activities |
|
18.35
+323.52%
|
4.33
-49.08%
|
8.51
+1711.17%
|
-0.53
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
2.34
-46.66%
|
4.38
-48.50%
|
8.51
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.11
|
0.00
|
0.00
-100.00%
|
0.06
|
| Net Other Financing Charges |
|
-0.31
-528.57%
|
-0.05
|
—
|
-0.58
|
| Changes In Cash |
|
10.64
+864.03%
|
-1.39
-1041.80%
|
-0.12
+98.71%
|
-9.46
|
| Beginning Cash Position |
|
2.00
-41.03%
|
3.40
-3.47%
|
3.52
-72.89%
|
12.97
|
| End Cash Position |
|
12.64
+531.62%
|
2.00
-41.03%
|
3.40
-3.47%
|
3.52
|
| Free Cash Flow |
|
-7.58
-32.40%
|
-5.72
+33.65%
|
-8.63
+3.37%
|
-8.93
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Common Stock Issuance |
|
2.34
-46.66%
|
4.38
-48.50%
|
8.51
|
0.00
|
| Issuance Of Capital Stock |
|
18.55
+323.33%
|
4.38
-48.50%
|
8.51
|
0.00
|
| Net Preferred Stock Issuance |
|
16.21
|
0.00
|
—
|
—
|
| Preferred Stock Issuance |
|
16.21
|
0.00
|
—
|
—
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|